COMPANY
PIPELINE
R&D
IR
PR
CAREERS
Anticipation Grows as Korean Fourth-Generation EGFR TKI Emerges: Thera..
Professor Byung Chul Cho MD, "TRX-221, top among all drug candidates" CEO Koo Lee PhD mentioned, "Pr..
Therapex Holds Clinical Advisory Board Meeting for Fourth-Generation N..
Therapex Holds Clinical Advisory Board Meeting for Fourth-Generation Non-Small Cell Lung Cancer Treatment Candidate &qu..
Therapex to Present "Fourth-Generation EGFR TKI" TRX-221 at ..
"IND application for Phase 1 study in Korea and the U.S. in the first half of this year... initiate clinical tria..
Therapex Signs MOU with WuXi AppTec for Anticancer Drug Development
A new partnership for the preclinical development of anticancer drug candidates and clinical sample production ▲ Fro..
Interpark Bio Convergence Signs Research Collaboration Agreement for T..
Mutual cooperation for the discovery of TPD anticancer agents... "Goal is to start preclinical development in 202..
IBCC to rename as "Therapex" and call for professional perso..
Therapex have scouted Director Jiyeon Park, Woo-sik Kim PhD, and Jaehong Lim PhD, and othersThe decision to change its ..
Interpark, after E-commerce, Is Now Making a Move in the Biotechnology..
Koo Lee PhD, CEO of Interpark Bio Convergence:Bachelor's degree in Chemistry Education from Seoul National University M..
Interpark Bio Convergence Recruits Specialized Personnel and Expands R..
New medicinal chemistry laboratory in Munjeong-dong research center aids in new drug discovery...targeting solid tumor..
Dr. Koo Lee, vice president of IBCC, to serve as a CEO
Vice President Koo Lee PhD, Promoted to CEO at Interpark Bio ConvergenceFormer CEO Jun Ho Hong transitions to GI Innov..
Interpark Bio Convergence Strikes Licensing Deal with BiSiChem for Ant..
Interpark Bio Convergence pledges 10 billion won to BiSiChem for the royalties of the anticancer drug candidateOn the 2..